Lv51
880 积分 2024-10-18 加入
Cagrilintide–semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study
1个月前
已关闭
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
1个月前
已完结
Impact of BMI and comorbidities on efficacy of once‐weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial
2个月前
已完结
The pathogenesis of IgA nephropathy and implications for treatment
2个月前
已完结
Epidemiology and determinants of obesity in China
2个月前
已完结
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
5个月前
已关闭
皖公网安备34019202002308
